Other studies showed that increased SGO1 can promote the proliferation and invasion of prostate cancer through AKT pathway, highlighting the potential of SGO1 as a new therapeutic target for prostate cancer 10, 11. This evidence concerns the gene AKT1 and prostate carcinoma.